Molecular Weight(MW): 415.57
Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
Purity & Quality Control
Choose Selective Prostaglandin Receptor Inhibitors
|Description||Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.|
Bimatoprost mildly stimulates the rate of aqueous humor flow during the day (13%) and at night (14%), its ocular hypotensive action is due primarily to a 26% reduction in the tonographic resistance to outflow. Bimatoprost enhances the pressure-sensitive outflow pathway.  Bimatoprost displaces [3H]prostaglandin F(2alpha) from FP receptors with K(i) of 6.31 μM. Bimatoprost rapidly mobilizes intracellular Ca(2+) via cloned human FP receptors expressed in human embryonic kidney cells and via native FP receptors in 3T3 mouse fibroblasts with EC(50) of 2.94 μM and 2.2 μM.  Bimatoprost up-regulates Cyr61 mRNA expression in the cat iris. Bimatoprost-induced up-regulation of Cyr61 mRNA expression is not because of the activation of the prostaglandin FP receptor but a different receptor.  Bimatoprost consistently evokes responses in different cells within the same tissue preparation, whereas prostaglandin F(2 alpha) and 17-phenyl prostaglandin F(2 alpha) elicites signaling responses in the same cells. Bimatoprost selectively stimulates intracellular calcium signaling in different cat iris sphincter cells. 
|In vivo||Bimatoprost is the ethyl amide derivative of 17-phenyl trinor PGF2α, a potent prostaglandin FP receptor agonist. Bimatoprost elicits an immediate, robust spike in [Ca2+] that rapidly decayes back to baseline levels. Bimatoprost possess direct agonist activities at the rat, mouse, and human FP prostanoid receptor. |
-  Brubaker RF, et al. Surv Ophthalmol, 2001, 45 Suppl 4, S347-351.
-  Sharif NA, et al. Eur J Pharmacol, 2001, 432(2-3), 211-213.
-  Liang Y, et al. J Biol Chem, 2003, 278(29), 27267-27277.
|In vitro||Ethanol||83 mg/mL (199.72 mM)|
|DMSO||36 mg/mL (86.62 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03891446||Recruiting||Drug: Bimatoprost SR||Open-Angle Glaucoma|Ocular Hypertension||Allergan||March 27 2019||Phase 3|
|NCT02676310||Terminated||Drug: Bimatoprost||Alopecia|Alopecia Androgenetic|Baldness||Allergan||March 2016||Phase 1|
|NCT00999557||Withdrawn||Drug: bimatoprost ophthalmic solution|Drug: placebo||Alopecia|Breast Cancer||Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)||January 2016||Not Applicable|
|NCT02444767||Completed||Drug: 13mg Bimatoprost Ocular Insert||Healthy Volunteers||ForSight Vision5 Inc.||March 2015||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.